Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Ensysce Biosciences Inc.

    NASDAQ: ENSC · Real-Time Price · USD
    2.26
    0.04 (1.80%)
    At close: Jun 27, 2025, 12:35 PM
    1.80%
    Bid 2.21
    Market Cap 5.36M
    Revenue (ttm) 2.81M
    Net Income (ttm) -6.82M
    EPS (ttm) 110.31
    PE Ratio (ttm) 0.02
    Forward PE -43.6
    Analyst n/a
    Ask 2.28
    Volume 20,507
    Avg. Volume (20D) 1,773,072
    Open 2.28
    Previous Close 2.22
    Day's Range 2.20 - 2.28
    52-Week Range 1.62 - 14.67
    Beta 0.98

    About ENSC

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol ENSC
    Website n/a
    Full Company Profile

    Next Earnings Release

    Ensysce Biosciences Inc. is scheduled to release its earnings on Aug 13, 2025, during market hours.
    Analysts project revenue of ... Unlock content with Pro Subscription

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    3 weeks ago
    +3.48%
    ENSC stock has given up its prior gain. Ensysce Bi... Unlock content with Pro Subscription
    3 weeks ago
    +3.48%
    Ensysce Biosciences shares are trading higher after the company announced it was awarded the second $5.3 million installment of a $15 million, three-year grant from the National Institute on Drug Abuse.
    news image

    2 days ago · accessnewswire.com

    Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2

    ~ Treatment to Evaluate Effect of Food on Overdose Protection of MPAR ~ ~ Grant Funds from NIDA Accelerating Clinical Development Program ~ SAN DIEGO, CALIFORNIA / ACCESS Newswire / June 24, 2025 / En...

    news image

    2 weeks ago · accessnewswire.com

    Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025

    ~ Pain Management, RE-Invented: A New Era for Analgesia ~ SAN DIEGO, CA / ACCESS Newswire / June 11, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharm...

    news image

    3 weeks ago · accessnewswire.com

    Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection

    ~ PF614-MPAR Moving to Next Stage of Development, Finalizing Drug Formulation ~ ~ Funds Accelerate Path Towards Commercialization ~ SAN DIEGO, CA / ACCESS Newswire / June 4, 2025 / Ensysce Biosciences...

    news image

    1 month ago · accessnewswire.com

    Ensysce Biosciences Reports First Quarter 2025 Financial Results

    Receives U.S. Patent for Groundbreaking Treatment for Opioid Use Disorder Clinical Trial on Novel Analgesic, PF614-MPAR, Demonstrates Overdose Protection SAN DIEGO, CA / ACCESS Newswire / May 13, 2025...

    news image

    1 month ago · accessnewswire.com

    Ensysce Biosciences Bolsters Management Team with Regulatory Expert

    ~ Advanced Preparation for New Drug Application ~ SAN DIEGO, CA / ACCESS Newswire / May 12, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical...

    news image

    2 months ago · accessnewswire.com

    Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

    SAN DIEGO, CA / ACCESS Newswire / April 24, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain reli...

    news image

    2 months ago · benzinga.com

    Ensysce Biosciences Stock Doubles In One Trading Session - Here's Why

    Ensysce Biosciences, Inc ENSC stock gained almost 100% with a strong session volume compared to the average volume of 81.23K, as per data from Benzinga Pro.

    news image

    2 months ago · accessnewswire.com

    Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds

    SAN DIEGO, CA / ACCESS Newswire / April 23, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain reli...

    news image

    2 months ago · accessnewswire.com

    Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder

    ~ Applies TAAP and MPAR Technology to Produce Novel OUD Treatments ~ ~ Prioritizes Safety and Tolerability for OUD Patients ~ SAN DIEGO, CA / ACCESS Newswire / April 23, 2025 / Ensysce Biosciences, In...

    news image

    2 months ago · accessnewswire.com

    Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study

    ~ Additional Evidence of PF614-MPAR Overdose Protection after Completion of Part 1 of Clinical Study ~ SAN DIEGO, CA / ACCESS Newswire / April 15, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensy...

    Add to Watchlist